CD19-targeting chimeric antigen receptor (CAR) T-cell therapy shows potential to intercept fibrotic organ manifestations and improve disease measures in patients with diffuse cutaneous systemic ...

The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis. "We have seen firsthand the transformative effects of KYV-101 in MG patients treated ...

What is the latest research on scleroderma? Find out in this collection of recent MEDLINE abstracts compiled by the editors at Medscape Nurses. Acute and chronic renal diseases remain common ...

The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...

AUSTIN — A group of researchers at the Hormel Institute in Austin recently published a scientific paper detailing a significant discovery in a group of diseases known as scleroderma. "Centromere ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

Autologous stem cell transplant for patients with diffuse systemic sclerosis (SSc), without selecting for a particular hematopoietic cell type, performed about as well in a new single-arm trial as was ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease ...

Please provide your email address to receive an email when new articles are posted on . A one-time infusion of BMS-986353, a CD19 CAR T-cell therapy, improved lung function and skin thickness.